Rigel Pharmaceuticals RIGL Development Milestones — Revenue recognized
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Rigel Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Rigel Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Rigel Pharmaceuticals's development milestones — revenue recognized.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Rigel Pharmaceuticals's development milestones — revenue recognized?
- Rigel Pharmaceuticals (RIGL) reported development milestones — revenue recognized of $0 in Q1 2026.
- How has Rigel Pharmaceuticals's development milestones — revenue recognized changed year-over-year?
- Rigel Pharmaceuticals's development milestones — revenue recognized decreased by 100.0% year-over-year, from $3M to $0.
- What does development milestones — revenue recognized mean?
- This metric represents revenue recognized from the achievement of specific clinical, regulatory, or commercial milestones stipulated in collaboration or licensing agreements. It reflects the successful progression of drug candidates through the development pipeline as defined by contractual obligations with external partners. Fluctuations in this metric indicate the timing and success rate of research and development activities rather than recurring product sales.